专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005072061A3 CONJUGATES FOR CANCER THERAPY AND DIAGNOSIS 审中-公开
标题翻译：癌症治疗与诊断相结合
公开(公告)号：WO2005072061A3
公开(公告)日：2006-08-24
申请号：PCT/IL2005000117
申请日：2005-02-02
申请人： BIOSIGHT LTD , GENGRINOVITCH STELA , IZAKOVICH ESTHER
发明人： GENGRINOVITCH STELA , IZAKOVICH ESTHER
IPC分类号： A01N37/18 , A61K47/48
CPC分类号： A61K47/48038 , A61K47/481 , A61K47/542 , A61K47/55
摘要： The present invention relates to conjugates of a drug and an amino acid or an amino acid derivative or analog, pharmaceutical compositions comprising the conjugates and methods of use thereof In particular, the present invention relates to conjugates of anti-proliferative drugs and asparagine and glutamine and analogs thereof as compositions for treatment of cancer, and conjugates of imaging agent carriers and amino acids for the diagnosis of tumors and metastases.
摘要翻译：本发明涉及药物和氨基酸或氨基酸衍生物或类似物的缀合物，包含缀合物的药物组合物及其使用方法。特别地，本发明涉及抗增殖药物和天冬酰胺和谷氨酰胺的缀合物，以及其类似物作为用于治疗癌症的组合物，以及用于诊断肿瘤和转移的成像剂载体和氨基酸的缀合物。

2. 发明申请

WO0220715A3 PEPTIDE CONJUGATED ANTI-CANCER PRODRUGS 审中-公开
标题翻译：肽联合抗癌药物
公开(公告)号：WO0220715A3
公开(公告)日：2006-01-12
申请号：PCT/IL0100839
申请日：2001-09-05
申请人： BIOSIGHT LTD , GENGRINOVITCH STELA
发明人： GENGRINOVITCH STELA
IPC分类号： A61K38/06 , A61K38/08 , A61K38/10 , A61K38/17 , A61K47/48 , A61K31/00 , A61K39/00
CPC分类号： A61K38/10 , A61K38/06 , A61K38/08 , A61K38/1709 , A61K47/65 , A61K2300/00
摘要： The present invention relates to pharmaceutical compositions comprising a targeting peptide, a protease specific cleavable peptide, and a chemotherapeutic drug that when conjugated are substantially inactive, but upon degradation of the cleavable sequence by a proteolytic enzyme abundant in or within that target cancer cell, the chemotherapeutic drug is released and becomes active, and to the use of these compositions for treatment of cancer.
摘要翻译：本发明涉及包含靶向肽，蛋白酶特异性可切割肽和化学治疗药物的药物组合物，当缀合基本上无活性时，但是当通过在该靶标癌细胞内或内的蛋白水解酶降解可切割序列时，化疗药物被释放并变得活性，并且使用这些组合物治疗癌症。

3. 发明专利

IL154696A PEPTIDE CONJUGATED ANTI-CANCER PRODRUGS 未知
公开(公告)号：IL154696A
公开(公告)日：2008-11-03
申请号：IL15469601
申请日：2001-09-05
申请人： BIOSIGHT LTD , GENGRINOVITCH STELA
发明人： GENGRINOVITCH STELA
IPC分类号： A61K31/00 , A61K38/06 , A61K38/08 , A61K38/10 , A61K38/17 , A61K47/42 , A61K47/48
摘要： The present invention relates to pharmaceutical compositions comprising a targeting peptide, a protease specific cleavable peptide, and a chemotherapeutic drug that when conjugated are substantially inactive, but upon degradation of the cleavable sequence by a proteolytic enzyme abundant in or within the target cancer cell 5, the chemotherapeutic drug is released and becomes active, and to the use of these compositions for treatment of cancer.

4. 发明申请

WO2006056984A3 CHELATING AND BINDING CHEMICALS TO A MEDICAL IMPLANT 审中-公开
标题翻译：化学和化学化学品到医疗植物
公开(公告)号：WO2006056984A3
公开(公告)日：2006-10-05
申请号：PCT/IL2005001247
申请日：2005-11-23
申请人： NOVIK SHAI , GENGRINOVITCH STELA
发明人： GENGRINOVITCH STELA
IPC分类号： A61L31/02 , A61L27/54 , A61L29/16 , A61L31/08 , A61L31/16
CPC分类号： A61L27/54 , A61L29/16 , A61L31/022 , A61L31/08 , A61L31/16 , A61L2300/416 , A61L2300/42 , A61L2300/80 , A61L2300/802 , A61N1/375
摘要： Chelating and binding chemicals to a medical implant, and therapeutic applications. Implantable 'metal chelated surface and chemical coated' medical implant device - drug (or biological moiety) coated or drug eluting stent, prosthesis, or other, includes a medical implant component having metal surface (M) with chemical entity (X) bound via chelator (C) chelated to the metal surface in an (M) - (C) - (X) configuration. Chelator or/and chemical entity - drug (or biological moiety), linker bonded to a drug (or biological moiety), other, are bound at surface concentration greater than 100 picograms per cm2. Manufacturing the implantable medical device. Medical implant system including medical implant component and delivery device for delivering and implanting medical implant component in a subject. Implanting the medical device. Preventing or/and treating medical conditions, such as restenosis or/and thrombosis, by implanting the medical device, wherein activity of bound chemical entity exhibits efficacy towards the medical condition.
摘要翻译：螯合和结合化学物质到医疗植入物，以及治疗应用。可植入的金属螯合表面和化学涂覆的医用植入装置 - 药物（或生物部分）涂覆或药物洗脱支架，假体或其他包括具有金属表面（M）的医用植入物组分，化学实体（X）通过螯合剂结合（C）以（M） - （C） - （X）构型螯合到金属表面。螯合剂或/和化学实体 - 药物（或生物学部分），与药物（或生物部分）结合的连接体，其他的结合物，其表面浓度大于100皮克/ cm 2。制造可植入医疗器械。医疗植入系统，包括用于在受试者中递送和植入医学植入物部件的医疗植入部件和递送装置。植入医疗器械。通过植入医疗装置来预防或/和治疗诸如再狭窄或/和血栓形成的医学状况，其中结合的化学实体的活性对医疗状况表现出有效性。

5. 发明申请

WO2004047720A3 METHODS OF INHIBITING ANGIOGENSIS VIA MODIFICATION OF A LYSYL OXIDASE 审中-公开
标题翻译：通过改变LYSYL氧化酶抑制血管生成的方法
公开(公告)号：WO2004047720A3
公开(公告)日：2006-02-16
申请号：PCT/IL0301008
申请日：2003-11-27
申请人： TECHNION RES & DEV FOUNDATION , NEUFELD GERA , AKIRI GAL , VADASZ ZAHAVA , GENGRINOVITCH STELA
发明人： NEUFELD GERA , AKIRI GAL , VADASZ ZAHAVA , GENGRINOVITCH STELA
IPC分类号： A61K20060101 , A61K6/00 , A61K38/44 , A61K39/395 , A61K48/00 , A61P35/00 , C07K16/30 , C07K16/40 , C12N9/06 , C12N15/53
CPC分类号： C12Q1/6886 , A61K38/00 , A61K2039/505 , C07K16/30 , C07K16/40 , C12N9/0022 , C12Q1/26 , C12Y104/03013 , G01N33/574 , G01N33/57419 , G01N2500/00
摘要： Methods and compositions suitable for modulating angiogenesis in a mammalian tissue are provided. Further provided are methods suitable for inhibiting metastasis and fibrosis in a mammalian tissue and for assessing the malignancy of colon cancer tumors.
摘要翻译：提供了适于调节哺乳动物组织中血管生成的方法和组合物。还提供了适合于抑制哺乳动物组织中的转移和纤维化并用于评估结肠癌肿瘤的恶性肿瘤的方法。

6. 发明专利

AU2016362239A1 Salts of conjugates for cancer therapy 未知
公开(公告)号：AU2016362239A1
公开(公告)日：2018-06-14
申请号：AU2016362239
申请日：2016-12-01
申请人： BIOSIGHT LTD
发明人： GENGRINOVITCH STELA
IPC分类号： C07H19/06 , A61K31/7068 , A61K47/50 , A61P35/00 , A61P35/02 , C07H19/067
摘要： The present invention relates to pharmaceutically acceptable salts of conjugates comprising a chemotherapeutic drug and an amino acid or a derivative thereof, which are readily taken up by a target cell and reduce side effects induced by the chemotherapeutic drug. In particular, the present invention relates to pharmaceutically acceptable salts of conjugates comprising cytidine analog drugs and aspartic or glutamic acid and analogs thereof, pharmaceutical compositions comprising these conjugates and use thereof for the treatment of cancer or a pre-cancer condition or disorder.

7. 发明专利

AU2001288025A8 Peptide conjugated anti-cancer prodrugs 未知
公开(公告)号：AU2001288025A8
公开(公告)日：2006-11-02
申请号：AU8802501
申请日：2001-09-05
申请人： BIOSIGHT LTD
发明人： GENGRINOVITCH STELA
IPC分类号： A61K31/00 , A61K38/06 , A61K38/08 , A61K38/10 , A61K38/17 , A61K39/00 , A61K47/48
摘要： The present invention relates to pharmaceutical compositions comprising a targeting peptide, a protease specific cleavable peptide, and a chemotherapeutic drug that when conjugated are substantially inactive, but upon degradation of the cleavable sequence by a proteolytic enzyme abundant in or within the target cancer cell 5, the chemotherapeutic drug is released and becomes active, and to the use of these compositions for treatment of cancer.

8. 发明专利

AU2016362830A1 Cytarabine conjugates for cancer therapy 未知
公开(公告)号：AU2016362830A1
公开(公告)日：2018-07-12
申请号：AU2016362830
申请日：2016-01-25
申请人： BIOSIGHT LTD
发明人： GENGRINOVITCH STELA , BEN YAKAR RUTH
IPC分类号： A61K31/7068 , A61P31/12 , A61P35/00 , A61P35/02
摘要： The present invention relates to conjugates comprising cytarabine and an amino acid for use in the treatment of cancer. In particular, the present invention relates to conjugates of cytarabine and aspartic acid for use in the treatment of hematological cancers in medically compromised patients.

9. 发明专利

CA3007065A1 SALTS OF CONJUGATES FOR CANCER THERAPY 未知
公开(公告)号：CA3007065A1
公开(公告)日：2017-06-08
申请号：CA3007065
申请日：2016-12-01
申请人： BIOSIGHT LTD
发明人： GENGRINOVITCH STELA
IPC分类号： C07H19/06 , A61K31/7068 , A61K47/50 , A61P35/00 , A61P35/02 , C07H19/067
摘要： The present invention relates to pharmaceutically acceptable salts of conjugates comprising a chemotherapeutic drug and an amino acid or a derivative thereof, which are readily taken up by a target cell and reduce side effects induced by the chemotherapeutic drug. In particular, the present invention relates to pharmaceutically acceptable salts of conjugates comprising cytidine analog drugs and aspartic or glutamic acid and analogs thereof, pharmaceutical compositions comprising these conjugates and use thereof for the treatment of cancer or a pre-cancer condition or disorder.

10. 发明专利

CA3069558A1 COMBINATION CANCER THERAPY 未知
公开(公告)号：CA3069558A1
公开(公告)日：2019-01-17
申请号：CA3069558
申请日：2018-07-09
申请人： BIOSIGHT LTD
发明人： BEN YAKAR RUTH , GENGRINOVITCH STELA , TESSLER SHOSHI , FLAISHON LIAT
IPC分类号： A61K31/7064 , A61K31/706 , A61P35/00 , C07H19/067
摘要： The present invention relates to combination therapies of a cytarabine conjugate and one or more anti-neoplastic agents for inhibiting cancer cell growth. In particular, the present invention relates to a conjugate of cytarabine and aspartic acid (BST-236) in combination with one or more additional anti-neoplastic agents for use in the treatment of hematological cancers.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式